Home › Funds › Second Line Capital, LLC › OCUL
Second Line Capital, LLC position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Second Line Capital, LLC reported holding 656,848 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 0.88% of its reported portfolio and ranking #22 among its reported holdings. Second Line Capital, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-10 · Source: SEC EDGAR Form 13F-HR
How Second Line Capital, LLC's OCUL position evolved
Second Line Capital, LLC first disclosed a stake in OCUL in Q2 2024 at 262,810 shares (US$1.8M). The position peaked in Q2 2026 at 638,640 shares, worth US$6.3M. Across 10 filings, Second Line Capital, LLC increased the stake 8 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 656,848 shares valued at US$5.0M — an increase of 18,208 shares quarter over quarter.. Notable position changes include a 29% increase in Q4 2024 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 262.81K | $1.80M | New |
| Q3 2024 | 262.81K | $2.29M | Hold |
| Q4 2024 | 340.10K | $2.90M | Add |
| Q1 2025 | 346.10K | $2.54M | Add |
| Q2 2025 | 385.47K | $3.58M | Add |
| Q3 2025 | 402.47K | $4.70M | Add |
| Q4 2025 | 500.75K | $6.08M | Add |
| Q1 2026 | 528.29K | $4.95M | Add |
| Q2 2026 | 638.64K | $6.27M | Add |
| Q3 2026 | 656.85K | $5.04M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 43 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- SUMMER ROAD LLC 12.21M sh · $119.89M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- Logos Global Management LP 5.30M sh · $52.05M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.48M sh · $24.32M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- TCG Crossover Management, LLC 1.65M sh · $16.18M · Q2 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on Second Line Capital, LLC
FAQ
How long has Second Line Capital, LLC held OCUL?
Second Line Capital, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Second Line Capital, LLC's current position in OCUL?
As of Q3 2026, Second Line Capital, LLC holds 656.85K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $5.04M, representing 0.88% of its reported portfolio and ranking #22.
Has Second Line Capital, LLC been buying or selling OCUL?
In the latest 13F filing (Q3 2026), Second Line Capital, LLC increased its position in OCUL. The position peaked in Q2 2026 at 638.64K shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.